Q2/2019 6/30/2019 EPS -0.070 ZacksConsensus -0.530 ActVsEst 0.460 - Beat
![Wall Street Horizon](../../../Content/images/providers/WH.png)
Arcturus Therapeutics Holdings Inc. (ARCT)
Last arcturus therapeutics holdings inc. earnings: 3/11 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.arcturusrx.com/investor-relations
Company Research
Source: Wall Street Horizon
![Wall Street Horizon](../../../Content/images/providers/WH.png)
Impact Snapshot
Event Time:
ARCT
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ARCT alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ARCT alerts
High impacting Arcturus Therapeutics Holdings Inc. news events
Weekly update
A roundup of the hottest topics
ARCT
News
- Arcturus Therapeutics Receives Clearance of an Investigational New Drug Application to U.S. Food and Drug Administration for ARCT-032, an Investigational Inhaled mRNA Therapeutic to Treat Cystic FibrosisBusiness Wire
- Does Arcturus Therapeutics (ARCT) Have the Potential to Rally 216.35% as Wall Street Analysts Expect? [Yahoo! Finance]Yahoo! Finance
- Arcturus Therapeutics to Attend Upcoming Investor & Scientific ConferencesBusiness Wire
- Arcturus Therapeutics Holdings Inc. (NASDAQ: ARCT) was upgraded by analysts at Leerink Partnrs to a "strong-buy" rating.MarketBeat
- Arcturus Therapeutics Holdings Inc. (NASDAQ: ARCT) is now covered by analysts at SVB Leerink LLC. They set an "outperform" rating and a $70.00 price target on the stock.MarketBeat
ARCT
Earnings
- 8/5/24 - Beat
ARCT
Sec Filings
- 8/13/24 - Form 8-K
- 8/5/24 - Form 10-Q
- 8/5/24 - Form 8-K
- ARCT's page on the SEC website